Skip to Main Content

Newly diagnosed lung cancer patients are half as likely to die of the disease if they take a Merck drug alongside standard chemotherapy, according to new trial data that eclipsed doctors’ expectations.

The trial, which compared a combination of chemo and Merck’s blockbuster Keytruda against chemo alone, found that patients in the combo group were 51 percent more likely to be alive after one year. Those getting Merck’s drug were also 48 percent less likely to have their cancer progress in the same period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I had to stop the keytruda. I have developed hypothyroidism and within the last couple months acute renal failure as a result of taking this medication. Still on high-dose steroids to try to correct the condition without help or Improvement so far

    • So sorry to hear that. My husband himself just started keytruda along with pem traxade. His first dose went well and he actually said that he felt better then he normally does so we’re praying that this works he’s now on maintenance therapy and has been for two years we realize the devastating possible side effects but feel the benefits far outweigh the risk for now we will keep you in our prayers good luck and I hope the side effects can be reversed keep your faith in God he is the ultimate position our faith is what has gotten us this far God bless

Comments are closed.